ScreenerHero

VSTMVerastem, Inc.

NAS · US · Technology · Biotechnology · verastem.com
6.890USD-5.55%Mkt Cap: 623.98M $P/E: —

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap623.98M $
Enterprise Value565.62M $
Revenue (TTM)87.53M $
Gross Profit25.62M $
Net Income (TTM)-209.47M $
Revenue/Share0.9850 USD
Last Price6.890 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees102
CountryUS
SectorTechnology
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.09
PEG—
EV/EBITDA-3.56
EV/Revenue6.46
P/S7.06
P/B12.36
EPS (TTM)-2.28
EPS (Forward)-0.75
52W Range
3.43044% of range11.25
52W High11.25 USD
52W Low3.430 USD
Profitability
Gross Margin82.86%
Oper. Margin-81.62%
EBITDA Margin-181.26%
Profit Margin-677.59%
ROE-366.23%
ROA-85.00%
Growth
Revenue Growth1775.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-137.51M $
CapEx (TTM)9.62M $
FCF Margin-118.17%
FCF Yield-16.58%
Net Debt-52.02M $
Net Debt/EBITDA0.33
Balance Sheet
Debt/Equity1.52
Current Ratio2.25
Quick Ratio2.12
Book Value/Sh0.5520 USD
Cash/Share1.506 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJun 1, 2023
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.75 USD
Upside (mean)+114.1%
Target Range9.000 USD – 18.00 USD
$9.000+114.1% to mean$18.00
# Analysts8
Ownership
Shares Out.90.56M
Float70.57M
Insiders0.90%
Institutions110.61%
Short Interest
Short Ratio7.7d
Short % Float22.04%
Short % Out.21.91%
Shares Short19.83M
Short (prev mo.)24.14M
Technical
SMA 505.411 (+27.3%)
SMA 2006.299 (+9.4%)
Beta0.29
S&P 52W Chg18.16%
Avg Vol (30d)2.20M
Avg Vol (10d)2.30M
Technical Indicators
RSI (14)61.5
MACD0.4623
MACD Signal0.4372
MACD Hist.+0.0251
BB Upper7.422 USD
BB Middle6.394 USD
BB Lower5.365 USD
BB Width32.17%
ATR (14)0.4609 USD
Vol Ratio (20d)0.50x